Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. (NASDAQ: ADTX) regularly issues news and regulatory updates that describe its activities as a social innovation platform accelerating promising health innovations. Company news often highlights developments across its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health, as well as platform-level initiatives such as the bitXbio™ strategy.
Recent announcements have focused on the evolution of Aditxt’s bitXbio™ framework, which the company describes as a transformational approach intended to connect public markets, blockchain and Web3 concepts, digital asset treasuries, and life sciences operating companies. News items have discussed proxy proposals related to an Employee Stock Purchase Plan, equity incentive plan changes, and a non-binding advisory vote on a proposed name change from “Aditxt, Inc.” to “bitXbio, Inc.”
Updates about Aditxt’s subsidiaries and ventures are another recurring theme. For example, the company has reported on Adimune, a wholly owned subsidiary developing a DNA-based therapeutic platform to reprogram the immune system, including information on its patent portfolio and plans related to first-in-human trials for conditions such as type 1 diabetes and stiff person syndrome. News has also covered Pearsanta, Aditxt’s precision diagnostics subsidiary, including the start of enrollment in a clinical study of the Mitomic® Endometriosis Test (MET™) and Pearsanta’s work with Mitomic® and Adductomics testing platforms.
Capital markets and corporate governance developments appear frequently in Aditxt’s news flow. The company has issued press releases about a 1-for-113 reverse stock split intended to address Nasdaq’s minimum bid price requirement, as well as proxy statements and special meetings to approve issuances of common stock underlying preferred stock and warrants, an Employee Stock Purchase Plan, and changes to its equity incentive plan.
Investors and observers who follow ADTX news can use this stream of press releases and related filings to track how Aditxt describes the progress of its platform strategy, its health-focused programs, its relationships with companies such as Evofem Biosciences, and its ongoing corporate and capital structure actions. Returning to this page provides a way to review the company’s official communications over time.
Aditxt (NASDAQ: ADTX) has announced that its Chief Innovation Officer, Dr. Shahrokh Shabahang, and Adimune's Co-CEO, Dr. Friedrich Kapp, will participate in the company's Weekly Update today at 11:30 a.m. ET. The virtual event will focus on discussing recent developments of ADI-100™, which is the lead therapeutic candidate of Adimune, Aditxt's wholly owned subsidiary. The event will be held virtually via Zoom, and interested participants can register through the provided link.
Aditxt (NASDAQ: ADTX) has announced that Dr. Charles Howe from Mayo Clinic's Neuroimmunology Department will join their Weekly Update on May 2, 2025. Dr. Howe, who chairs the Division of Experimental Neurology and directs Research at Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology, will discuss findings from a recent preclinical study of ADI-100™, the lead therapeutic candidate from Aditxt's subsidiary Adimune™.
The virtual event will also feature Dr. Shahrokh Shabahang, Aditxt's Chief Innovation Officer, and Dr. Friedrich Kapp, Adimune's Co-CEO. The update is scheduled for 11:30 a.m. ET via Zoom.
Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received IRB approval to begin a clinical study for the Mitomic® Endometriosis Test (MET), a blood-based diagnostic tool for endometriosis detection. The study will evaluate MET's performance against laparoscopic diagnosis, enrolling up to 1,000 participants starting May 2025.
The study aims to assess MET's sensitivity and specificity across disease subtypes, explore correlations between test results and symptoms, and establish a biobank for future research. MET utilizes mitochondrial DNA biomarkers to detect disease signatures through a simple blood draw, potentially offering a non-invasive alternative to surgical diagnosis.
Endometriosis affects 1 in 10 women globally, with diagnosis typically taking 7-10 years due to current diagnostic limitations. The study results will support MET's launch as a Laboratory Developed Test at Pearsanta's CLIA/CAP-certified laboratory in Richmond, Virginia.
Aditxt (NASDAQ: ADTX) announced positive results from Mayo Clinic pre-clinical studies for its subsidiary Adimune's lead therapeutic candidate ADI-100. The study, led by Mayo Clinic's neuroimmunology team, validated that ADI-100 induces immune tolerance to glutamic acid decarboxylase (GAD), a key autoantigen in multiple autoimmune conditions.
Key findings include:
- Confirmation of ADI-100's safety profile with no increased T cell reactivity to GAD
- Dendritic cells treated with ADI-100 showed increased tolerogenic markers
- ADI-100-induced tolerogenic dendritic cells reduced activation of T cells from GAD-sensitive patients
The findings were presented at the American Academy of Neurology Annual Meeting. With pre-clinical efficacy and safety studies complete and GMP manufacturing finalized, Adimune plans regulatory submissions for the second half of 2025, targeting subsequent first-in-human clinical trials.
Aditxt (NASDAQ: ADTX), a social innovation platform focused on health innovations, has announced its Weekly Update event scheduled for today at 11:30 a.m. ET. The virtual meeting will address several key developments, including the company's recent achievement of regaining compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market.
The event will also provide updates on the company's operating subsidiaries and discuss ongoing strategic transactions. The meeting will be held virtually via Zoom, with registration required for attendance.
Aditxt (NASDAQ: ADTX) has successfully regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). As a result, the previously scheduled hearing before the Hearings Panel for April 22, 2025, has been cancelled. The company will continue trading on the Nasdaq Capital Market under the symbol ADTX.
The social innovation platform, focused on accelerating promising health innovations in areas including autoimmunity and cancer, received official notification from the Nasdaq Stock Market's Listing Qualifications Department confirming their compliance status.
Aditxt (NASDAQ: ADTX) announced that Appili Therapeutics' President and CEO Don Cilla will join Aditxt's Weekly Update on April 4, 2025. The event will focus on emerging infectious diseases and provide updates on the Appili transaction and operational highlights.
Key highlights include $117 million in submitted federal funding applications and Appili's track record of securing $33.2 million in prior government awards. The update will also cover modifications to the United States Air Force Academy Cooperative Agreement for ATI-1701, a biodefense vaccine candidate, featuring an increased General & Administrative overhead recovery rate that will be applied retroactively.